{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:38:31Z","timestamp":1782243511919,"version":"3.54.5"},"reference-count":67,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natioinal Research Council of Thaland (NRCT)","award":["RTA6180006"],"award-info":[{"award-number":["RTA6180006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Infections due to carbapenem-resistant Escherichia coli (CREC) are problematic due to limitation in treatment options. Combination therapies of existing antimicrobial agents have become a reliable strategy to control these infections. In this study, the synergistic effects of meropenem in combination with aminoglycosides were assessed by checkerboard and time-kill assays. Of the 35 isolates, 19 isolates (54.3%) were resistant to carbapenems (imipenem and meropenem) with the MIC ranges from 16 to 128 \u00b5g\/mL. These isolates were resistant to almost all antibiotic classes. Molecular characteristics revealed co-harboring of carbapenemase (blaNDM-1, blaNDM-5 and blaOXA-48) and extended-spectrum \u03b2-lactamases (ESBL) genes (blaCTX-M, blaSHV and blaTEM). The checkerboard assay displayed synergistic effects of meropenem and several aminoglycosides against most CREC isolates. Time-kill assays further demonstrated strong synergistic effects of meropenem in combination with either amikacin, gentamicin, kanamycin, streptomycin, and tobramycin. The results suggested that meropenem in combination with aminoglycoside therapy might be an efficient optional treatment for infections cause by CREC.<\/jats:p>","DOI":"10.3390\/antibiotics10081023","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T10:24:17Z","timestamp":1629714257000},"page":"1023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-Resistant Escherichia coli Harboring blaNDM-1 and blaNDM-5"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3016-3049","authenticated-orcid":false,"given":"Pawarisa","family":"Terbtothakun","sequence":"first","affiliation":[{"name":"Division of Biological Science, Faculty of Science and Natural Product Research Center of Excellence, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0949-592X","authenticated-orcid":false,"given":"Ozioma Forstinus","family":"Nwabor","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyaluck","family":"Siriyong","sequence":"additional","affiliation":[{"name":"Traditional Thai Medical Research and Innovation Center, Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supayang P.","family":"Voravuthikunchai","sequence":"additional","affiliation":[{"name":"Division of Biological Science, Faculty of Science and Natural Product Research Center of Excellence, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-2518","authenticated-orcid":false,"given":"Sarunyou","family":"Chusri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai 90110, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"Doi","year":"2017","journal-title":"Virulence"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajic.2019.10.006","article-title":"Clinical characteristics, risk factors, and outcomes of patients hospitalized in the US military health system with carbapenem-resistant Enterobacteriaceae infection","volume":"48","author":"Adams","year":"2020","journal-title":"Am. J. Infect. Control"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-021-00950-7","article-title":"Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016\u20132018","volume":"10","author":"Paveenkittiporn","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14787210.2018.1436966","article-title":"Management of infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: Current evidence and future prospects","volume":"16","author":"Sheu","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cmi.2019.03.030","article-title":"Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients","volume":"25","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of Carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fmicb.2013.00048","article-title":"\u201cStormy waters ahead\u201d: Global emergence of carbapenemases","volume":"4","author":"Patel","year":"2013","journal-title":"Front. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkz501","article-title":"Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: A multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae","volume":"75","author":"Hayakawa","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01882-17","DOI":"10.1128\/AAC.01882-17","article-title":"Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network","volume":"62","author":"Zhang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: A new option for MDR Gram-negative infections","volume":"71","author":"Falcone","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkt118","article-title":"Activity of biapenem (RPX2003) combined with the boronate \u03b2-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00115-18","DOI":"10.1128\/CMR.00115-18","article-title":"NDM Metallo-\u03b2-Lactamases and Their Bacterial Producers in Health Care Settings","volume":"32","author":"Wu","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2147\/IDR.S225546","article-title":"Characterization Of bla (NDM-5)-Positive Escherichia coli Prevalent In A University Hospital In Eastern China","volume":"12","author":"Sun","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1128\/AAC.03911-14","article-title":"blaNDM-5 carried by an IncX3 plasmid in Escherichia coli sequence type 167","volume":"58","author":"Yang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13756-018-0349-6","article-title":"Dissemination of bla(NDM-5) gene via an IncX3-type plasmid among non-clonal Escherichia coli in China","volume":"7","author":"Li","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options","volume":"10","author":"Sheu","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pacios, O., Blasco, L., Bleriot, I., Fernandez-Garcia, L., Gonz\u00e1lez Bardanca, M., Ambroa, A., L\u00f3pez, M., Bou, G., and Tom\u00e1s, M. (2020). Strategies to Combat Multidrug-Resistant and Persistent Infectious Diseases. Antibiotics, 9.","DOI":"10.3390\/antibiotics9020065"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nwabor, O.F., Terbtothakun, P., Voravuthikunchai, S.P., and Chusri, S. (2021). Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030185"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ontong, J.C., Ozioma, N.F., Voravuthikunchai, S.P., and Chusri, S. (2021). Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0244673"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jiac.2020.11.004","article-title":"In vitro synergistic activity of fosfomycin in combination with other antimicrobial agents against carbapenem-resistant Klebsiella pneumoniae isolated from patients in a hospital in Thailand","volume":"27","author":"Chukamnerd","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/IDR.S292431","article-title":"In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant Klebsiella pneumoniae with Different Resistance Mechanisms in China","volume":"14","author":"Liu","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkx539","article-title":"Meropenem potentiation of aminoglycoside activity against Pseudomonas aeruginosa: Involvement of the MexXY-OprM multidrug efflux system","volume":"73","author":"Poole","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/IDR.S192540","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae: A 5-year experience at a tertiary care hospital","volume":"12","author":"Chotiprasitsakul","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13756-019-0668-2","article-title":"Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5\u2009year (2011\u20132016) case-control study","volume":"9","author":"Presterl","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae","volume":"31","author":"Machuca","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012\u20132013","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"ref_32","first-page":"839","article-title":"Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals","volume":"64","author":"Han","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.49.4.1629-1632.2005","article-title":"Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations","volume":"49","author":"Sun","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vattimo Mde, F., Watanabe, M., da Fonseca, C.D., Neiva, L.B., Pessoa, E.A., and Borges, F.T. (2016). Polymyxin B Nephrotoxicity: From Organ to Cell Damage. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161057"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/TCRM.S199119","article-title":"Fosfomycin: The characteristics, activity, and use in critical care","volume":"15","author":"Hashemian","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist. Updates"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106019","DOI":"10.1016\/j.ijantimicag.2020.106019","article-title":"Co-occurrence of aminoglycoside and \u03b2-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland","volume":"56","author":"Bodendoerfer","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Iredell, J., Brown, J., and Tagg, K. (2016). Antibiotic resistance in Enterobacteriaceae: Mechanisms and clinical implications. BMJ, 352.","DOI":"10.1136\/bmj.h6420"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: The versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Okoche, D., Asiimwe, B.B., Katabazi, F.A., Kato, L., and Najjuka, C.F. (2015). Prevalence and Characterization of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral Hospital, Uganda. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135745"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/jac\/dkx521","article-title":"A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Boutal","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Suay-Garc\u00eda, B., and P\u00e9rez-Gracia, M.T. (2019). Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030122"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"30461","DOI":"10.2807\/1560-7917.ES.2017.22.6.30461","article-title":"Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014","volume":"22","author":"Dortet","year":"2017","journal-title":"Eurosurveillance"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/1469-0691.12719","article-title":"The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide","volume":"20","author":"Nordmann","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2147\/IDR.S208231","article-title":"Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012\u20132015","volume":"12","author":"Chang","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4155\/fmc-2016-0015","article-title":"New Delhi metallo-\u03b2-lactamase-1: Structure, inhibitors and detection of producers","volume":"8","author":"Groundwater","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12606","DOI":"10.1074\/jbc.RA118.003835","article-title":"Evolution of New Delhi metallo-\u03b2-lactamase (NDM) in the clinic: Effects of NDM mutations on stability, zinc affinity, and mono-zinc activity","volume":"293","author":"Cheng","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4155\/fmc-2017-0143","article-title":"Structural and functional insight of New Delhi Metallo \u03b2-lactamase-1 variants","volume":"10","author":"Khan","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/IDR.S232010","article-title":"Molecular Mechanisms and Epidemiology of Carbapenem-Resistant Escherichia coli Isolated from Chinese Patients During 2002\u20132017","volume":"13","author":"Tian","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Netikul, T., and Kiratisin, P. (2015). Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0139116"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18521","DOI":"10.1038\/s41598-019-55008-x","article-title":"Genomic characterization of an emerging bla(KPC-2) carrying Enterobacteriaceae clinical isolates in Thailand","volume":"9","author":"Kerdsin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1600-0463.2007.00722.x","article-title":"Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae","volume":"115","author":"Monstein","year":"2007","journal-title":"APMIS"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00722-17","DOI":"10.1128\/AAC.00722-17","article-title":"Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling","volume":"61","author":"Yadav","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1128\/AAC.37.4.715","article-title":"Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect","volume":"37","author":"Kadurugamuwa","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, present, and future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00002018-200730080-00002","article-title":"Safety profile of meropenem: An updated review of over 6,000 patients treated with meropenem","volume":"30","author":"Linden","year":"2007","journal-title":"Drug Saf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: A review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","article-title":"Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: The pitfalls of aminoglycoside susceptibility","volume":"15","author":"Zavascki","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/106002800303700203","article-title":"Aminoglycoside-associated nephrotoxicity in the elderly","volume":"37","author":"Baciewicz","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2332-0877.1000207","article-title":"Effect of antibiotics combination and comparison of methods for detection of synergism in multiresistant Gram-negative bacteria","volume":"3","author":"Leite","year":"2015","journal-title":"J. Infect. Dis. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dki477","article-title":"In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis","volume":"57","author":"Petersen","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","unstructured":"CLSI (2018). Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100, Clinical and Laboratory Standards Institute."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fcimb.2018.00363","article-title":"In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and\/or Colistin-Resistant Enterobacteriaceae","volume":"8","author":"Smani","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/8\/1023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:49:51Z","timestamp":1760165391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/8\/1023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["antibiotics10081023"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10081023","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}